Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer.
Immunomedics (IMMU) came out with a quarterly loss of $0.30 per share versus a loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.
If you found this site useful and want to help keep it alive,
to cover the costs and keep the site free of advertisements! Thank you for your support!